p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.

Silvestrini, Rosella; Benini, Elvira; Veneroni, Silvia; Daidone, Maria Grazia; Tomasic, Gorana; Squicciarini, Paolo; Salvadori, B

doi:10.1200/jco.1996.14.5.1604

Cited by 142 publications

(101 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings were in parallel with those results in colorectal cancer, breast cancer, non-small-cell lung cancer, renal cancer and head and neck cancer. (Ofner et al, 1995;Silvestrini et al, 1996;Fontanini et al, 1995;Hirata et al, 2009;Lehnerdt et al, 2009). Accordingly in those studies Increased Bcl-2 expression is associated to favorable outcome.…”

Section: Discussionmentioning

confidence: 97%

Low Expression of the bcl2 Gene in Gastric Adenocarcinomas in Mazandaran Province of Iran

Mirmajidi¹,

Ataee²,

Barzegar³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Gastric cancer accounts for about 8% of the total cancer cases and 10% of total cancer deaths worldwide. It is the second lethal cancer after esophageal cancer and is considered the fourth most common cancer in north and northwest Iran. The bcl2 family has a key role in the regulation of apoptosis and change in its expression can contribute to cancer. This study initially scheduled to determine the expression of bcl2 gene in tissue samples of adenocarcinoma cancer patients. Materials and Methods: A total of 10 samples of gastric adenocarcinoma and 10 of normal tissues from Sari hospital were selected and after DNA extraction from tissues, bcl2 gene expression assayed by real-time PCR. Results: Our results demonstrated higher expression of the bcl2 gene in control compared with cancer and marginal cancer tissues. Conclusions: On one hand BCL2 plays an important role as an oncogene to inhibit apoptosis; on the other hand, it can initiate cell cycle arrest at G0 stage. Our observed association between its expression and patient survival is quite conflicting and may be tissue-specific. The data suggest expression both tumoural and non-tumoral(marginal) groups have lowered expression than controls (P>0.05). Due to the low number of samples we could not examine the relationship with clinicopathological features. However, bcl-2 expression may be important for prognostic outcome or a useful target for therapeutic intervention.

show abstract

Section: Discussionmentioning

confidence: 97%

Low Expression of the bcl2 Gene in Gastric Adenocarcinomas in Mazandaran Province of Iran

Mirmajidi¹,

Ataee²,

Barzegar³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Furthermore, they all lack PR expression (Lykkesfeldt et al, 1994(Lykkesfeldt et al, , 1995. Several clinical studies have shown that the Bcl-2 expression in breast tumours is strongly correlated to both ERα and PR expression, and Bcl-2 expression is an indicator of a favourable outcome following endocrine treatment (Gee et al, 1994;Lipponen et al, 1995;Silvestrini et al, 1996;Elledge et al, 1997;Keen et al, 1997;Kobayashi et al, 1997;Olopade et al, 1997;Holmqvist et al, 1999). The decreased Bcl-2 expression associated with decreased ERα expression, and lack of response to antioestrogens observed in the resistant cell lines is in concert with the above-mentioned clinical studies.…”

Section: Discussionmentioning

confidence: 99%

Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells

2001

View full text Add to dashboard Cite

Summary Most breast cancer patients treated with anti-oestrogens will eventually develop resistance towards treatment. Therefore it is important to find new therapeutic agents effective for treatment of patients relapsing on anti-oestrogen. The vitamin D analogue EB1089 (Seocalcitol TM ) is a promising new agent for treatment of breast cancer patients with advanced disease, and in this study we show that two different anti-oestrogen-resistant human breast cancer cell lines are more sensitive towards treatment with EB1089, than the parent MCF-7 cell line. The two resistant cell lines both express a lower content of the anti-apoptotic protein Bcl-2, and we suggest that this may explain the higher sensitivity towards EB1089. The importance of Bcl-2 for response to EB1089 is supported by our observation that oestradiol abrogates the effect of EB1089 in cell lines which increase Bcl-2 in response to oestradiol treatment. Overall these results indicate that treatment with Seocalcitol TM may prove effective when patients become refractory to anti-oestrogen therapy, and that Bcl-2 may be used as a predictive marker.

show abstract

“…The survival of patients presenting tumours which express Bcl-2 protein may be better, unchanged, or worse than of those with similarly classi®ed tumours which lack Bcl-2 (Campos et al, 1993;Herod et al, 1996;Lepelley et al, 1995;Pezzella et al, 1992;Piris et al, 1994) and high Bcl-2 expression has been reported to be associated with low tumour cell proliferation (Silvestrini et al, 1996;Wilson et al, 1997). Whilst a number of explanations may be o ered to account for such observations, our results suggest that di erential e ects of Bcl-2 on cell cycle arrest, the activity of wt p53 and the availability of additional, micro-environmental signals that promote cell survival or cell growth may critically determine ultimate tumour cell fate.…”

Section: Discussionmentioning

confidence: 99%

Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following γ-irradiation

et al. 1997

View full text Add to dashboard Cite

p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.

Abstract: p53 expression appears to be indicative of clinical outcome in postmenopausal patients treated with tamoxifen. Whether p53 overexpression and weak bcl-2 expression are indicators of biologic aggressiveness, regardless of treatment, or of hormone resistance remains to be defined.

Cited by 142 publications

References 14 publications

Low Expression of the bcl2 Gene in Gastric Adenocarcinomas in Mazandaran Province of Iran

Low Expression of the bcl2 Gene in Gastric Adenocarcinomas in Mazandaran Province of Iran

Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells

Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following γ-irradiation

Contact Info

Product

Resources

About